A Study to Identify and Characterize LAL-D Patients in High-risk Populations

Study Identifier:
LAL-CSS01
ClinicalTrials.gov Identifier:
NCT02345421
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
    Date
    Dec 2014 - Sep 2015
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: 2+ years
    Requirements Information
    Sex
    Female & Male
    Age
    2+ years

    Study Details

    Medical Condition
    • Unmapped
    Study Drug
      Date
      Dec 2014 - Sep 2015
      Phase 1
      Phase 2
      Phase 3
      Phase 4
      N/A
      Patient Requirements
      Sex: Female & Male
      Age: 2+ years years
      Requirements Information

      Protocol Summary

      The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.

      Trial Locations

      Location
      Status
      Location
      Birmingham, Alabama, United States
      Status
      N/A
      Location
      Phoenix, Arizona, United States
      Status
      N/A
      Location
      Los Angeles, California, United States
      Status
      N/A
      Location
      San Francisco, California, United States
      Status
      N/A
      Location
      Gainesville, Florida, United States
      Status
      N/A
      Location
      Jacksonville, Florida, United States
      Status
      N/A